课题基金 / 基金详情

Extracellular vesicles encapsulating CRISPR machinery for treatment of SARS-CoV-2 infection

Extracellular vesicles encapsulating CRISPR machinery for treatment of SARS-CoV-2 infection
封装 CRISPR 机制的细胞外囊泡用于治疗 SARS-CoV-2 感染
批准号:
10655147
负责人:
Houjian Cai
金额:
$22.2万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-01-19 至 2024-12-31

项目摘要

项目成果

Houjian Cai的其他基金

相似基金

相关文献

中文摘要
翻译
摘要/文摘
英文摘要
Summary/Abstract SARS-CoV-2 has caused the deaths of millions of people globally. Effective antiviral therapeutic treatment options are urgently needed. CRISPR-mediated genome editing has provided a very promising avenue for treatment of a variety of genetic diseases. Particularly, the CRISPR-Cas13 system has been demonstrated to possess the potential of inhibiting SARS-CoV-2 and influenza infections by degradation of viral genomic RNA and viral mRNA. However, it is still very challenging to deliver the CRISPR machinery to initiate genome editing efficiently in vivo. Extracellular vesicles (EVs) contain a variety of molecular components including lipids, mRNA, microRNAs, and proteins. A large body of studies has shown that EVs mediate cell-to-cell communication by transmitting their encapsulated contents. This proposal intends to construct EVs encapsulating the CRISPR machinery and deliver the EVs to respiratory epithelial cells to inhibit SARS-CoV-2 proliferation in vivo. We will therefore genetically engineer the Cas13d protein so that Cas13d/CRISPR-RNA (crRNA) ribonucleoprotein complex can be encapsulated into EVs. We will also engineer the membrane of EVs, such that EVs target respiratory epithelial cells and deliver Cas13d/crRNA for inhibiting SARS-CoV-2 viral assembly and proliferation, thereby inhibiting COVID-19. This study will allow us to understand the feasibility of an EVs-based vehicle to deliver genome editing machinery to inhibit SARS-CoV-2 proliferation in lung epithelial cells. This study will provide a treatment option for COVID-19 patients to reduce disease severity and mortality.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Heparan Sulfate in Prostate Cancer
  • 批准号:
    10825084
  • 项目类别:
  • 资助金额:
    $37.47万
  • 财政年份:
    2023
  • 负责人:
    Houjian Cai
  • 依托单位:
Blocking TMPRSS2 expression for prevention of SARS-CoV-2 infection
  • 批准号:
    10303752
  • 项目类别:
  • 资助金额:
    $22.65万
  • 财政年份:
    2021
  • 负责人:
    Houjian Cai
  • 依托单位:
Blocking TMPRSS2 expression for prevention of SARS-CoV-2 infection
  • 批准号:
    10449301
  • 项目类别:
  • 资助金额:
    $18.88万
  • 财政年份:
    2021
  • 负责人:
    Houjian Cai
  • 依托单位:
Heparan Sulfate in Prostate Cancer
  • 批准号:
    9914542
  • 项目类别:
  • 资助金额:
    $56.17万
  • 财政年份:
    2018
  • 负责人:
    Houjian Cai
  • 依托单位:
国内基金
海外基金
ACE2/AGXT2信号轴在甲基异柳磷诱导斑马鱼神经发育异常过程中的作用机制研究
  • 批准号:
    JCZRLH202600625
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
ACE2 Ser623磷酸化调控MED1促VSMCs功能损伤在移植血管重构中的作用及机制研究
  • 批准号:
    2026JJ50619
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    翁春艳
  • 依托单位:
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介 导“肠-胰岛 ”轴血糖调控功能的降糖机制研 究
  • 批准号:
    Y24H280055
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    颜美秋
  • 依托单位: